Fred Hutchinson Cancer Center
Why trials sponsored by Fred Hutchinson Cancer Center stopped, in this sample of ClinicalTrials.gov.
16 stopped trials with a clear reason; 100% ended for non-scientific reasons.
| Reason | Trials | Share |
|---|---|---|
| funding or business | 7 | 44% |
| slow enrollment | 7 | 44% |
| regulatory or ethics | 1 | 6% |
| staffing, sites or logistics | 1 | 6% |
Trials
- ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
NCT04579523 · WITHDRAWN · slow enrollment
“Study withdrawn before opening to accrual.” - A Novel Mobile Health Intervention for Improving Tobacco Cessation Among Young Adults
NCT07571018 · TERMINATED · funding or business
“Discontinuation of funding” - Evaluating the Effects of an Exercise Intervention on the Gut Microbiota in Stage II-III Colorectal Cancer Survivors
NCT05930496 · TERMINATED · slow enrollment
“Terminated due to low accrual.” - Helping Ovarian Cancer Patients Cope With Their Illness (HOPE)
NCT06666218 · SUSPENDED · staffing, sites or logistics
“Enrollment is currently paused. Aim 1 recruitment has finished, and the study team is preparing to begin Aim 2 recruitment.” - Clinical Decision Support Tools to Increase Human Papillomavirus (HPV) Vaccination in Adolescents in Pharmacies
NCT05831540 · TERMINATED · slow enrollment
“This study has been terminated due to the conclusion of funding. We were able to collect data on primary outcomes through pharmacy staff, but due to recruitment challenges were not able to complete secondary outcome recruitment.” - Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia
NCT04994808 · TERMINATED · funding or business
“The study was closed due to the end of funding.” - A Tailored Screening and Smoking Cessation Program for the LGBTQ Community of Seattle
NCT05304390 · TERMINATED · funding or business
“Terminated due to end of funding. Enrollment sufficient to evaluate primary and secondary outcomes measures.” - Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study
NCT05135650 · TERMINATED · regulatory or ethics
“Terminated due to FDA withdrawal of the emergency use authorization (EUA) for sotrovimab” - eHealth Diet and Physical Activity Program for the Improvement of Health in Rural Latino Cancer Survivors
NCT04081298 · TERMINATED · slow enrollment
“Terminated due to slow accrual.” - Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation
NCT03602898 · WITHDRAWN · funding or business
“Insufficient funding” - Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
NCT03195010 · TERMINATED · slow enrollment
“Terminated because of slow recruitment and lack of funding support” - Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma
NCT02584829 · TERMINATED · funding or business
“Terminated due to loss in funding” - Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
NCT02408016 · TERMINATED · funding or business
“Terminated due to loss of funding” - Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT01076270 · TERMINATED · funding or business
“Funding withdrawal” - Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT01028716 · TERMINATED · slow enrollment
“The study experienced lower accrual rates after the onset of COVID. Upon review of the collected data it was deemed that an adequate amount of subjects has been enrolled to date to assess study aims.” - Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
NCT00555048 · TERMINATED · slow enrollment
“Low accrual”
Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.